QGEN NYSE Russell 1000 Earnings call
Qiagen (QGEN) · Q2 2026 results and valuation
Share price: $50.30 · 2026-11-11
Results Q2 2026 vs Q4 2025 · previous quarter · published 6 Aug 2026 and 5 Feb 2026
Management sounded upbeat, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
—
No financial figures for this pair
Outlook given
2 · How management spoke
Upbeat
More upbeat than 72% of company calls
Answers to analysts: typical, in line with the script.
Similar to last call.
3 · What stood out
Figure
QGEN increased its annual dividend by 40% in 2026 due to the company's financial strength.
Valuation
Is Qiagen undervalued?
Reverse DCF. Free cash flow from the last full fiscal year (2025-12-31), grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
At −0.8% growth a year (3-year revenue growth), the model's fair value is $19.88 a share — the stock trades 153% above it. Today's price assumes 11.0% growth a year.
Current price
$50.30
close of 2026-11-11
Market implies growth of iThe yearly free-cash-flow growth, for the next 10 years, that today’s share price already assumes. If you believe the company grows faster than this, the stock is cheap under this model; slower, and it is expensive.
+11.0% for 10 yrs
Fair value / share
$19.88
Buy below
$14.91
Price vs fair value
Overvalued 153%
Price vs buy-below price
Overvalued >200%
Read between the lines
-
Key theme
The adjusted operating income margin was 29.4% compared with 29.9% in the second quarter of '25.
Source quote
“The adjusted operating income margin was 29.4% compared with 29.9% in the second quarter of '25. Adjusted operating income declined 2% and reached USD 157 million. Disciplined cost management and efficiency gains helped offset gross margin headwinds.”
-
Guidance
For the full year, Qiagen is reaffirming its outlook for total net sales growth of about 1 to 2 percentage points at CER.
-
Last period
New product launches, including the 3 new sample prep instruments as well as new offerings for QIAstat-Dx and QIAcuity are expected…
Source quote
“New product launches, including the 3 new sample prep instruments as well as new offerings for QIAstat-Dx and QIAcuity are expected... As a first point, the comparison impact from the roll-off headwinds from NeuMoDx and Dialunox contributes about 2 percentage points of incremental growth. As a next point, acceleration year-over-year growth from QuantiFERON starting in the second quarter of '26 is...”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q4 2025.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“As Thierry highlighted, we delivered a better-than-expected second quarter, exceeding our outlook for both sales and adjusted diluted EPS while maintaining a high level of profitability.”
“As latent tuberculosis screening continues to expand, laboratories are looking for more efficient ways to manage growing testing volumes.”
“Our high level of profitability and cash generation continues to support a strong balance sheet.”
Topics
Most discussed now
- Generally accepted accounting principles or GAAP, that provide additional insights into Qiagen's performance.
- Sample Technologies led the quarter, reflecting continued demand for Qiagen's sample preparation solutions.
- Immigration testing demand decrease is what Qiagen highlighted at the end of its Q1 2026.
- Sample Technologies rose 9% CER, driven by automated consumables and higher instrument sales compared to the year ago period.
- However, this was more than offset by lower respiratory panel sales against a challenging prior year comparison previously communicated.
Faded since Q4 2025
- Dropped Qiagen continues to operate amid macroeconomic uncertainty, cautious capital spending and ongoing volatility, which requires discipline and…
- Fading Qiagen's strong free cash flow enabled us to make investments into bolt-on deals like Parse and Genoox, while also returning...
- Fading Despite cautious capital spending, Qiagen's sample technologies installed base grew to around 31,400 cumulative placements.
- Fading One example is Qiagen's liquid biopsy sample preparation portfolio, which grew by more than 30%, reflecting this increasing relevance in...